Evidence map›Paper›PMID 40034328›Full record

ArticleHeliyon2025

A VAT1-related gene signature predicts radioresistance in gliomas.

Xia Shan, Zhiyan Sun, Ruoyu Huang, Kuanyu Wang, Xiaoguang Qiu, Pei Yang

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xia ShanDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zhiyan SunDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Ruoyu HuangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Kuanyu WangDepartment of Gamma Knife, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xiaoguang QiuDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Pei YangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Radiotherapy is a vital postoperative adjuvant treatment for gliomas. However, radioresistance seriously affect the treatment efficacy. Excavating the feature of radioresisrtance in gliomas comprehensively are necessary. Methods: In the training set, 191 patients from the Chinese Glioma Genome Atlas (CGGA) were included, of which all patients had received postoperative radiotherapy. The epidemiological data and RNA sequencing data of 430 patients with whole grade glioma were obtained from the Cancer Genome Atlas (TCGA), which was used for validation. Results: Based on the Lasso regression analysis, five-gene signature was established which was associated with VAT1-related radioresistance in gliomas. High-risk patients showed higher proportion of elders, high-grade glioma, oligodendroglial histology and IDH wild type. The risk score was identified as an independent prognostic factor in the CGGA dataset, and the high-risk score impaired the overall survival time. The biological processes of positively expressed genes of risk score were functionally involved in inflammatory and immune response. And the activation of signaling pathways in high-risk score group also showed close correlation with tumor occurrence, progression and immune microenvironment. What's more, the immune cell infiltration analysis showed that high-risk score indicated decreased CD8 Conclusion: The five-gene signature can predict the survival of patients with glioma received postoperative radiotherapy efficiently. The immunosuppressive microenvironment, as a feature of glioma, potentially devote to the radioresistance.

Indexed as

GliomaImmunosuppressionPrognosisRadioresistance

Identifiers

PMID40034328
PMCPMC11875813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.